Current strategies to create tailored and risk-adapted therapies for CLL patients

Best Pract Res Clin Haematol. 2016 Mar;29(1):111-121. doi: 10.1016/j.beha.2016.08.010. Epub 2016 Aug 12.

Abstract

Given the current dynamics in the development of novel agents for CLL therapy, the task to find optimal, non-toxic combinations has become the primary goal. This article gives an update of the most interesting novel drugs. The strategy of the German CLL Study Group to use these agents in combinations is described in detail, highlighting the strategy and first results of a recently started series of phase II combination trials, the BXX series using agents such as bendamustine, idelalisib, ibrutinib, obinutuzumab, ofatumumab and venetoclax.

Keywords: CLL; Ibrutinib; Idelalisib (CAL-101); MRD; Maintenance; Obinutuzumab (GA101); Ofatumumab; Venetoclax (ABT-199).

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bendamustine Hydrochloride / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
  • Clinical Trials, Phase II as Topic
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Precision Medicine / methods*
  • Precision Medicine / standards
  • Purines / therapeutic use
  • Pyrazoles / therapeutic use
  • Pyrimidines / therapeutic use
  • Quinazolinones / therapeutic use
  • Risk Factors
  • Sulfonamides / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bridged Bicyclo Compounds, Heterocyclic
  • PCI 32765
  • Purines
  • Pyrazoles
  • Pyrimidines
  • Quinazolinones
  • Sulfonamides
  • Bendamustine Hydrochloride
  • ofatumumab
  • venetoclax
  • obinutuzumab
  • idelalisib